Breaking News Instant updates and real-time market news.

CRSP

CRISPR Therapeutics

$21.24

0.49 (2.36%)

16:40
03/20/17
03/20
16:40
03/20/17
16:40

CRISPR Therapeutics says CFO Becker to go on family leave

CRISPR Therapeutics disclosed in a regulatory filing that effective March 21, Marc Becker, Senior Vice President and CFO of CRISPR Therapeutics, who has served as the company's CFO since February 2016, will go on a family and medical leave of absence. The company currently plans to provide an update on the status of Mr. Becker's leave of absence prior to the end of the second quarter. During Mr. Becker's leave of absence and effective March 21, Samarth Kulkarni, Ph.D., the company's Chief Business Officer will serve as the company's acting principal financial officer and Michael Esposito, the Company's Senior Director, Controller, will serve as the company's acting principal accounting officer.

CRSP CRISPR Therapeutics
$21.24

0.49 (2.36%)

11/14/16
11/14/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Conagra Brands (CAG) initiated with a Neutral at UBS. 2. CRISPR Therapeutics (CRSP) initiated with an Overweight at Barclays, an Overweight at Piper Jaffray, and a Buy at Guggenheim. 3. Forterra (FRTA) initiated with a Neutral at Goldman, an Outperform at RBC Capital, a Buy at Citi, an Outperform at Oppenheimer, a Hold at Deutsche Bank, and a Buy at SunTrust. 4. iRhythm Technologies (IRTC) initiated with an Overweight at JPMorgan, a Buy at BTIG, a Buy at Canaccord, and an Overweight at Morgan Stanley. 5. Teva (TEVA) reinstated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/16
SBSH
11/15/16
INITIATION
Target $19
SBSH
Neutral
CRISPR Therapeutics initiated with a Neutral at Citi
Citi analyst Yigal Nochomovitz started CRISPR Therapeutics with a Neutral rating and $19 price target. The risk/reward is balanced with the stock up 25% since the initial public offering, Nochomovitz tells investors in a research note. The analyst sees "no clear winner" in the gene editing patent debate.
02/15/17
JEFF
02/15/17
NO CHANGE
JEFF
Patent ruling best case for Editas Medicine, says Jefferies
Jefferies analyst Gena Wang views the United States Patent and Trademark Office's judgment of "no interference-in-fact" for the CRISPR/Cas9 interference motion phase as the "best case" for Editas Medicine (EDIT), Broad Institute's licensee. The analyst sees three choices for The University of California, which has CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) as licensees: Appeal, seek second interference, or discuss a settlement. Wang sees cross-licensing as the likely eventual path taken by both parties. CRISPR and Intellia could license from Editas the use of CRISPR in eukaryotic cells, while Editas could license from the two companies the use of single guide and tracrRNA, the analyst tells investors in a research note. She believes a royalty could be in the mid-single-digit range. Shares of Editas are up 33% to $24.99 in afternoon while CRISPR is down 13% to $15.05 and Intellia is down 11% to $12.26.
02/16/17
PIPR
02/16/17
NO CHANGE
Target $21
PIPR
Overweight
Piper's Schimmer calls CRISPR selloff 'major overreaction'
Piper Jaffray analyst Joshua Schimmer views yesterday's selloff in shares of CRISPR Therapeutics (CRSP) as a "major overreaction." The stock closed yesterday down 8%, or $1.36, to $15.90 after the patent office did not allow the patent interference with UC Berkeley versus Broad Institute over a Crispr/Cas-9 patent. Now that it's deemed patentable, CRISPR will move forward to get its own claims issued and likely move towards a second interference, Schimmer tells investors in a research note. CRISPER and Intellia Therapeutics (NTLA) are essentially litigation partners against the Broad, and now have the chance to win by knocking out Editas Medicine's (EDIT) single-guide tracr patent or by showing it was the first to invent and reduce to practice the application in eukaryotes, the analyst contends. Schimmer says he can't understand why Editas' valuation is higher than CRISPR's. He believes it should be the opposite. The analyst keeps an Overweight rating on CRISPR with a $21 price target.

TODAY'S FREE FLY STORIES

BPI

Bridgepoint Education

$12.29

-0.98 (-7.39%)

16:32
07/26/17
07/26
16:32
07/26/17
16:32
Earnings
Bridgepoint Education reports Q2 EPS 21c, consensus 23c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 10

    Aug

BDGE

Bridge Bancorp

$32.90

-0.7 (-2.08%)

16:32
07/26/17
07/26
16:32
07/26/17
16:32
Earnings
Breaking Earnings news story on Bridge Bancorp »

Bridge Bancorp reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

QEP

QEP Resources

$9.27

0.07 (0.76%)

16:31
07/26/17
07/26
16:31
07/26/17
16:31
Earnings
QEP Resources reports Q2 adjusted EPS (12c), consensus (20c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

MPWR

Monolithic Power

$106.79

1.86 (1.77%)

16:31
07/26/17
07/26
16:31
07/26/17
16:31
Earnings
Breaking Earnings news story on Monolithic Power »

Monolithic Power sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 08

    Aug

  • 10

    Aug

  • 15

    Aug

UDR

UDR, Inc.

$39.19

0.51 (1.32%)

16:31
07/26/17
07/26
16:31
07/26/17
16:31
Earnings
UDR, Inc. backs FY17 EPS view of 31c-36c, consensus 28c »

Reaffirmed FFO per share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FFIV

F5 Networks

$128.20

0.18 (0.14%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
F5 Networks sees Q4 non-GAAP EPS $2.20-$2.23, consensus $2.24 »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 05

    Sep

MPWR

Monolithic Power

$106.79

1.86 (1.77%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Monolithic Power reports Q2 EPS 68c, consensus 67c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 08

    Aug

  • 10

    Aug

  • 15

    Aug

O

Realty Income

$57.92

0.49 (0.85%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Realty Income reports Q2 EPS 30c, consensus 32c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FMNB

Farmers National Banc

$14.35

-0.4 (-2.71%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Farmers National Banc reports Q2 EPS 21c, consensus 22c »

Total loans were $1.51…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRCY

Mercury Systems

$43.86

-0.13 (-0.30%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Hot Stocks
Mercury Systems receives $5.5M order »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 07

    Aug

ESND

Essendant

$13.41

-0.42 (-3.04%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Essendant sees FY17 sales decline of 6%-9%, consensus $5.22B »

Management said, "In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Options
Preliminary option volume of 17.4M today »

Preliminary option volume…

NTRI

Nutrisystem

$62.95

1.3 (2.11%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Hot Stocks
Breaking Hot Stocks news story on Nutrisystem »

Nutrisystem trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

UDR

UDR, Inc.

$39.19

0.51 (1.32%)

16:29
07/26/17
07/26
16:29
07/26/17
16:29
Earnings
UDR, Inc. reports Q2 AFFO 43c vs. 41c last year »

UDR reports Q2 Funds from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FFIV

F5 Networks

$128.20

0.18 (0.14%)

16:29
07/26/17
07/26
16:29
07/26/17
16:29
Earnings
F5 Networks reports Q3 non-GAAP EPS $2.03, consensus $2.03 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 05

    Sep

FORR

Forrester

$41.60

0.15 (0.36%)

16:29
07/26/17
07/26
16:29
07/26/17
16:29
Earnings
Forrester sees FY17 pro forma EPS $1.13-$1.20, consensus $1.17 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BAC

Bank of America

$24.21

-0.27 (-1.10%)

, PYPL

PayPal

$58.79

0.53 (0.91%)

16:29
07/26/17
07/26
16:29
07/26/17
16:29
Hot Stocks
PayPal, BofA partner to enable in-store payments and account linking »

Bank of America (BAC) and…

BAC

Bank of America

$24.21

-0.27 (-1.10%)

PYPL

PayPal

$58.79

0.53 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 09

    Aug

  • 10

    Aug

AXTI

AXT, Inc.

$7.60

0.25 (3.40%)

16:28
07/26/17
07/26
16:28
07/26/17
16:28
Earnings
AXT, Inc. reports Q2 EPS 5c, consensus 5c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 03

    Aug

  • 10

    Aug

  • 19

    Sep

UDR

UDR, Inc.

$39.19

0.51 (1.32%)

16:28
07/26/17
07/26
16:28
07/26/17
16:28
Earnings
UDR, Inc. reports Q2 EPS 3c, consensus 6c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

ESND

Essendant

$13.41

-0.42 (-3.04%)

16:28
07/26/17
07/26
16:28
07/26/17
16:28
Earnings
Essendant reports Q2 adjusted EPS 28c, consensus 37c »

Reports Q2 revenue $1.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

KS

KapStone

$22.52

-0.17 (-0.75%)

16:28
07/26/17
07/26
16:28
07/26/17
16:28
Earnings
KapStone reports Q2 adjusted EPS 27c, consensus 27c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FORR

Forrester

$41.60

0.15 (0.36%)

16:28
07/26/17
07/26
16:28
07/26/17
16:28
Earnings
Forrester sees Q3 pro forma EPS 21c-25c, consensus 26c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

AHL

Aspen Insurance

$51.00

-0.75 (-1.45%)

16:27
07/26/17
07/26
16:27
07/26/17
16:27
Earnings
Aspen Insurance reports Q2 ops EPS 47c, consensus $1.00 »

Chris O'Kane, Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

OKE

Oneok

$55.59

-0.19 (-0.34%)

16:27
07/26/17
07/26
16:27
07/26/17
16:27
Hot Stocks
Oneok raises quarterly dividend 21% to 74.5c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

MB

Mindbody

$26.10

-0.05 (-0.19%)

16:27
07/26/17
07/26
16:27
07/26/17
16:27
Earnings
Breaking Earnings news story on Mindbody »

Mindbody sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.